CPIX News and Press, Cumberland Pharmaceuticals Inc. From 10/10/23

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE PR Newswire NASHVILLE, Tenn. , Oct. 10, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agen...

2023-10-06 13:29:08 ET Gainers: Falcon's Beyond Global  (FBYD) +145% . American Oncology Network  ( AONC ) +53% . Akso Health Group  ( AHG ) +23% . Vigil Neuroscience  ( VIGL ) +20% . NuScale Power Corporation ( SMR )...

2023-08-12 04:21:09 ET Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Conference Call August 08, 2023, 04:30 PM ET Company Participants Molly Aggas - IR A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Conference ...

2023-08-08 17:12:18 ET Cumberland Pharmaceuticals press release ( NASDAQ: CPIX ): Q2 GAAP EPS of $0.06. Revenue of $10.9M (+5.8% Y/Y). $89.4 million in total assets, $52.5 million in total liabilities, and $36.8 million of shareholders' equity at the end of June 2023. ...

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 PR Newswire NASHVILLE, Tenn. , Aug. 8, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced significantly i...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release ...

NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS PR Newswire NASHVILLE, Tenn. , June 26, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced the pub...

2023-05-23 10:53:28 ET The US FDA has cleared Cumberland Pharmaceuticals' ( NASDAQ: CPIX ) Investigational New Drug application for ifetroban for idiopathic pulmonary fibrosis. The IND is for a phase 2 study of the selective thromboxane receptor antagonist candidate. ...

CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS PR Newswire Cumberland initiating Phase II FIGHTING FIBROSIS ™ clinical trial, Newest program in Cumberland's ifetroban pipeline NA...

CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS PR Newswire Caldolor ® is the only injectable non-opioid approved for treating pain in infants NASHV...